Company intelligence / Profile preview
GenomeFrontier Therapeutics, Inc.
New Taipei or Taipei City, New Taipei City or Taipei City, Taiwangenomefrontier.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Preclinical
01
Overview
GenomeFrontier has demonstrated robust preclinical efficacy with its lead CAR-T program, GF-CART01, which eradicated Raji tumor cells in mouse models and maintained tumor-free status after rechallenge. The company’s pipeline includes additional CAR-T and TCR therapies targeting hematologic malignancies and solid tumors. Clinical development appears to be at the preclinical or early clinical stage for most programs[3].
- Therapeutic areas
- Oncology
- Modalities
- Gene therapy (virus-free)Cell therapy (CAR-T, TCR-T)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Collaboration with ADVA Bio on automated virus-free CAR-T cell production system[3].
Beyond the preview
Go deeper on GenomeFrontier Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GenomeFrontier Therapeutics, Inc..